<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040794</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02821</org_study_id>
    <secondary_id>CALGB-30106</secondary_id>
    <secondary_id>CDR0000069407</secondary_id>
    <secondary_id>U10CA031946</secondary_id>
    <nct_id>NCT00040794</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
  <official_title>ZD1839 (NSC #715055, IND #61187) With Induction Paclitaxel And Carboplatin Followed By Either Radiation Or Concomitant Radiation With Weekly Paclitaxel And Carboplatin In Stage III Non-Small Cell Lung Cancer, A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II clinical trial studies how well combining different regimens of chemotherapy
      and gefitinib with radiation therapy work in treating patients with stage III non-small cell
      lung cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor
      cells, either by killing the cells or by stopping them from dividing. Biological therapies
      such as gefitinib may interfere with the growth of tumor cells and slow the growth of
      non-small cell lung cancer. Radiation therapy uses high-energy x-rays to damage tumor cells.
      Giving different regimens of combination therapy together with gefitinib and radiation
      therapy may be an effective treatment for non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine whether ZD1839 (gefitinib) at 250 mg orally every day administered
      concomitantly with radiotherapy after induction treatment consisting of paclitaxel,
      carboplatin, and ZD1839 among patients with inoperable stage III non-small cell lung cancer
      and Common Terminology Criteria (CTC) performance status 2 or poor risk performance status
      0-1 is tolerable.

      II. To determine whether ZD1839 at 250 mg orally every day administered concomitantly with
      paclitaxel, carboplatin, and radiation after induction treatment consisting of paclitaxel,
      carboplatin, and ZD1839 among patients with inoperable stage III non-small cell lung cancer
      and CTC performance status 0-1 is tolerable.

      III. To determine the overall response rate, failure-free survival, and survival after
      treatment with induction chemotherapy with daily ZD1839, concomitant radiotherapy and daily
      ZD1839, and post-radiotherapy single agent daily ZD1839 among patients with CTC performance
      status 2 or poor risk performance status 0-1 and inoperable stage III non-small cell lung
      cancer.

      IV. To determine the overall response rate, failure-free survival, and survival after
      treatment with induction chemotherapy and daily ZD1839, concomitant chemoradiotherapy and
      daily ZD1839, and post-radiotherapy single agent daily ZD1839 among patients with CTC
      performance status 0-1 and inoperable stage III non-small cell lung cancer.

      V. To determine if elevated circulating epidermal growth factor receptor (EGFR) levels prior
      to treatment, as determined by either quantitative polymerase chain reaction (PCR) or direct
      enzyme-linked immunosorbent assay (ELISA) measurement, may predict for response to therapy
      with EGFR inhibitors.

      OUTLINE:

      All patients receive induction therapy comprising paclitaxel IV over 3 hours followed by
      carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses.
      Patients then receive therapy based on their assigned stratum.

      STRATUM I: Patients receive gefitinib orally (PO) daily for 7 weeks. Patients also undergo
      concurrent radiotherapy once daily 5 days a week for 7 weeks.

      STRATUM II: Patients receive gefitinib and radiotherapy as in stratum I concurrently with
      paclitaxel IV over 1 hour followed by carboplatin over 30 minutes once weekly for 7 weeks.

      Patients then receive gefitinib PO daily in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 1 year and
      then every 6 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (Stratum I)</measure>
    <time_frame>From randomization until death or last known follow-up, assessed up to 10 months</time_frame>
    <description>Kaplan-Meier curves will be used to describe overall survival in each stratum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (Stratum I)</measure>
    <time_frame>From randomization until death or last known follow-up, assessed up to 13 months</time_frame>
    <description>Kaplan-Meier curves will be used to describe overall survival in each stratum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (Stratum II)</measure>
    <time_frame>From randomization until death or last known follow-up, assessed up to 14.5 months</time_frame>
    <description>Kaplan-Meier curves will be used to describe overall survival in each stratum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The frequency of toxicity occurrence will be tabulated by the most severe occurrence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Failure-free survival</measure>
    <time_frame>Time between randomization and disease progression, death, or last known follow-up, assessed up to 3 years</time_frame>
    <description>Kaplan-Meier curves will be used to describe failure-free survival in each stratum. Within each treatment group, the pattern of treatment failure (local, distant, regional) will be summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to induction treatment</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Summarized by treatment group. Exact binomial confidence intervals will be computed for these response rates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Overall response to the full treatment regimen will be summarized by treatment group. Exact binomial confidence intervals will be computed for these response rates.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Adenocarcinoma of the Lung</condition>
  <condition>Adenosquamous Cell Lung Cancer</condition>
  <condition>Bronchoalveolar Cell Lung Cancer</condition>
  <condition>Large Cell Lung Cancer</condition>
  <condition>Squamous Cell Lung Cancer</condition>
  <condition>Stage IIIA Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Stratum I (gefitinib, radiotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gefitinib orally (PO) daily for 7 weeks. Patients also undergo concurrent radiotherapy once daily 5 days a week for 7 weeks.
Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum II (gefitinib, radiotherapy, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gefitinib and radiotherapy as in stratum I concurrently with paclitaxel IV over 1 hour followed by carboplatin over 30 minutes once weekly for 7 weeks.
Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Stratum II (gefitinib, radiotherapy, chemotherapy)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Stratum II (gefitinib, radiotherapy, chemotherapy)</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Stratum I (gefitinib, radiotherapy)</arm_group_label>
    <arm_group_label>Stratum II (gefitinib, radiotherapy, chemotherapy)</arm_group_label>
    <other_name>Iressa</other_name>
    <other_name>ZD 1839</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radiotherapy</description>
    <arm_group_label>Stratum I (gefitinib, radiotherapy)</arm_group_label>
    <arm_group_label>Stratum II (gefitinib, radiotherapy, chemotherapy)</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Stratum I (gefitinib, radiotherapy)</arm_group_label>
    <arm_group_label>Stratum II (gefitinib, radiotherapy, chemotherapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically documented non-small cell lung cancer (NSCLC),
             including squamous cell carcinoma, adenocarcinoma (including bronchoalveolar cell),
             and large cell anaplastic carcinoma (including giant and clear cell carcinomas)

          -  ELIGIBLE DISEASE STAGES: Inoperable IIIA and selected IIIB

               -  Generally, patients entered must be considered unresectable or inoperable;
                  patients with T1 or T2, N2 disease are eligible; patients with T3, N2 or T4,
                  N0-N2 disease are eligible if based on the closeness to the carina, invasion of
                  the mediastinum or invasion of the chest wall; patients with T3, N0-N1 disease
                  are not eligible; patients must be M0 (M1 patients are not eligible)

                    -  Patients with direct invasion of vertebral body are ineligible

                    -  Patients with tumors adjacent to a vertebral body are eligible, unless there
                       is demonstrable bone invasion, as long as all gross disease can be
                       encompassed in the radiation boost field in accordance with the homogeneity
                       criteria

                    -  Patients with contralateral mediastinal disease (N3) are eligible if all
                       gross disease can be encompassed in the radiation boost field in accordance
                       with the homogeneity criteria; patients with scalene, supraclavicular, or
                       contralateral hilar node involvement are ineligible

                    -  Patients with a pleural effusion, which is a transudate, cytologically
                       negative and non-bloody, are eligible if the radiation oncologist feels the
                       tumor can be encompassed within a reasonable field of radiotherapy. Patients
                       with exudative, bloody, or cytologically malignant effusions are not
                       eligible; if a pleural effusion can be seen on the chest computed tomography
                       (CT) but not on chest x-ray (CXR) and is too small to tap, the patient will
                       be eligible; a pleural effusion appearing only after a thoracotomy or other
                       invasive thoracic procedure was attempted will not make a patient ineligible

          -  PATIENTS MUST HAVE MEASURABLE DISEASE

               -  Lesions that can be accurately measured in at least one dimension (longest
                  diameter to be recorded) as &gt;= 20 mm with conventional techniques or as â‰¥10 mm
                  with spiral CT scan

               -  Lesions that are not considered measurable include the following:

                    -  Bone lesions

                    -  Leptomeningeal disease

                    -  Ascites

                    -  Pleural/pericardial effusion

                    -  Abdominal masses that are not confirmed and followed by imaging techniques

                    -  Cystic lesions

                    -  Tumor lesions situated in a previously irradiated area

          -  PRIOR THERAPY

               -  &gt;= 2 weeks since formal exploratory thoracotomy.

               -  No prior chemotherapy or radiation therapy for NSCLC

          -  CTC performance status 0-2

          -  No &quot;currently active&quot; second malignancy other than non-melanoma skin cancers; patients
             are not considered to have a &quot;currently active&quot; malignancy if they have completed
             therapy and are considered by their physician to be at less than 30% risk of relapse

          -  Non-pregnant and non-nursing because of significant risk to the fetus/infant

          -  No patients with uncontrolled intercurrent illness including, but not limited to,
             ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements

          -  No patients with chronic gastrointestinal disorders including liver disease, diarrheal
             or emetic disorders, or malabsorptive conditions which could worsen toxicity or limit
             efficacy of ZD1839

          -  No cytochrome P450 3A4 (CYP3A4) inducers within 7 days prior to starting protocol
             therapy and while on protocol treatment. CYP3A4 inducers: phenytoin, carbamazepine,
             barbiturates, rifampicin, dexamethasone, and St John's Wort; single doses of
             dexamethasone used as an antiemetic are permitted

          -  No human immunodeficiency virus (HIV)-positive patients receiving combination
             anti-retroviral therapy

          -  Granulocytes &gt;= 1,500/ul

          -  Platelets &gt;= 100,000/ul

          -  Calculated creatinine clearance &gt;= 20 cc/min

          -  Bilirubin &lt; 1.5 mg/dl

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) &lt; 2
             x upper limit of normal (ULN)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal Ready</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer and Leukemia Group B</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer and Leukemia Group B</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma, Bronchiolo-Alveolar</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

